FAK and MEK inhibitor combinations have previously been reported in uveal melanoma [42,43], RAS-dependent tumors [47], and NF1-related peripheral nerve sheath tumors [48], although clinical efficacy has not been observed in [non-stratified] patients with advanced solid tumors, such as mesothelioma and pancreatic ductal adenocarcinoma [49,50]. This evidence concerns the gene NF1 and pancreatic ductal adenocarcinoma.